Gsk (GLAXF) Depreciation & Amortization (CF) (2011 - 2013)

Gsk's Depreciation & Amortization (CF) history runs 3 years deep, the most recent figure standing at $35.6 million for Q4 2013.

• In Q4 2013, Depreciation & Amortization (CF) rose 10.9% year-over-year to $35.6 million; the TTM figure through Sep 2014 stood at $35.6 million (up 10.9% YoY), while the FY2018 annual figure was $1.3 billion, changed 0.11% from the prior year.
• Depreciation & Amortization (CF) was $35.6 million for Q4 2013 at Gsk, up from $32.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $35.6 million in Q4 2013 to a low of $32.1 million in Q4 2012.
• Historically, Depreciation & Amortization (CF) has averaged $33.6 million across 3 years, with a median of $33.0 million in 2011.
• The sharpest annual moves came in 2012 and 2013: Depreciation & Amortization (CF) decreased 2.68% in 2012, then rose 10.9% in 2013.
• A 3-year view of Depreciation & Amortization (CF) shows it stood at $33.0 million in 2011, then slipped by 2.68% to $32.1 million in 2012, then increased by 10.9% to $35.6 million in 2013.
• The last three Depreciation & Amortization (CF) figures came in at $35.6 million (Q4 2013), $32.1 million (Q4 2012), and $33.0 million (Q4 2011), per Business Quant data.